China, AstraZeneca

China Has Detained Senior AstraZeneca Executive
Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese government is probing AstraZeneca employees, the drugmaker says.
Pharma Giant AstraZeneca Says China Chief Detained
Pharmaceutical giant AstraZeneca said Thursday that the head of its China operations had been detained, after reports the firm was under investigation for potentially illegal data collection and drug imports.
AstraZeneca Says Current, Former Executives Involved in China Probe
Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe into alleged breaches of laws around drug importation and data privacy, the company said.
AstraZeneca's China chief in custody, believes unrelated to insurance probe
AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not know the reason, it did not believe it was linked to a large health insurance fraud case involving the company.
AstraZeneca extends losses as Chinese probe widens
AstraZeneca (AZN) stock falls as a Chinese probe into drug importations and data privacy implicates senior and former executives of the company.
AstraZeneca Falls Most Since 2020 as China Probe Fears Mount
AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns over a Chinese probe into the UK drugmaker.
AstraZeneca: China's investigation into exec separate from medical insurance probe
AstraZeneca said on Wednesday that to its knowledge an ongoing investigation by Chinese authorities into the company's top executive in the country, Leon Wang, is separate from a large health insurance fraud case also involving the company.
AstraZeneca falls on reports of Chinese probe
Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of senior executives in the company's China subsidiary have been implicated in an insurance fraud case.
AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy the stock as the big ...
AstraZeneca shares fall on report of potential China probe fallout
(Reuters) -AstraZeneca shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the ...
BioSpace1d
AstraZeneca’s Stock Price Takes a Hit as China Chief Investigated for Insurance Fraud
BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...
FiercePharma1d
UPDATED: AstraZeneca stock tanks over fears of expanding China fraud probe
AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...
Wall Street Journal3d
AstraZeneca Says Obesity Pill Shows Minimal Side Effects in Early Trial
AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The ...
AstraZeneca says experimental obesity pill safe in early-stage trial
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
MarketWatch2d
AstraZeneca PLC ADR rises Monday, outperforms market
The AstraZeneca PLC ADR AZN inched 0.01% higher to $71.43 Monday, on what proved to be an all-around grim trading session ...
Business Times9h
AstraZeneca’s US$1.5 billion manufacturing plant to create over 800 jobs in Singapore
ASTRAZENECA plans to hire more than 800 employees in Singapore including engineering, technical services and global supply chain roles at its upcoming US$1.5 billion Singapore manufacturing facility ...